Payment overview · 2025
General Payments
$295.41
9 reported records · 3 companies
Healthcare provider profile · identity verified
Mohammed M Rahman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JAMAICA, NY · NPI 1194811521
Verified facts
What the public records show
CMS Open Payments records show Mohammed M Rahman, MD received $295.41 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 59.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $174.82 | 59.2% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $96.78 | 32.8% | 5 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $23.81 | 8.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $295.41 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $96.78 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.82 | 2 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 184 |
| Losartan Potassium | Losartan Potassium | 574 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 486 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 69 |
| Gabapentin | Gabapentin | 409 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 335 | 84 |
| Metformin Hcl | Metformin Hcl | 325 | 73 |
| Famotidine | Famotidine | 304 | 73 |
| Eliquis | Apixaban | 302 | 50 |
| Montelukast Sodium | Montelukast Sodium | 302 | 93 |
| Furosemide | Furosemide | 274 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 233 | 63 |
| Simvastatin | Simvastatin | 211 | 36 |
| Mirtazapine | Mirtazapine | 204 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 180 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 58 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 162 | 49 |
| Donepezil Hcl | Donepezil Hcl | 149 | 29 |
| Memantine Hcl | Memantine Hcl | 146 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 43 |
| Omeprazole | Omeprazole | 138 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 17 |
| Baclofen | Baclofen | 121 | 12 |
| Levetiracetam | Levetiracetam | 114 | 18 |
| Lisinopril | Lisinopril | 110 | 29 |
| Xarelto | Rivaroxaban | 102 | 13 |
| Atenolol | Atenolol | 97 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 19 |
| Glipizide Er | Glipizide | 96 | 18 |
| Carvedilol | Carvedilol | 89 | 29 |
| Sertraline Hcl | Sertraline Hcl | 86 | 16 |
| Lactulose | Lactulose | 84 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 83 | 38 |
| Nifedipine Er | Nifedipine | 81 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 11 |
| Potassium Chloride | Potassium Chloride | 77 | 23 |
| Trazodone Hcl | Trazodone Hcl | 76 | 15 |
| Finasteride | Finasteride | 75 | 26 |
| Januvia | Sitagliptin Phosphate | 75 | 12 |
| Meloxicam | Meloxicam | 74 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 73 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 72 | 15 |
| Folic Acid | Folic Acid | 71 | 16 |
| Glimepiride | Glimepiride | 70 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 18 |
| Spironolactone | Spironolactone | 66 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 65 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 65 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 65 | 20 |
| Azithromycin | Azithromycin | 62 | 47 |
| Warfarin Sodium | Warfarin Sodium | 62 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 12 |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Myrbetriq | Mirabegron | 58 | suppressed |
| Allopurinol | Allopurinol | 57 | 13 |
| Sodium Chloride | 0.9 % Sodium Chloride | 57 | 35 |
| Meclizine Hcl | Meclizine Hcl | 56 | 15 |
| Metformin Hcl Er | Metformin Hcl | 54 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 53 | suppressed |
| Methimazole | Methimazole | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 12 |
| Farxiga | Dapagliflozin Propanediol | 47 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | suppressed |
| Cephalexin | Cephalexin | 42 | 27 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 42 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Latanoprost | Latanoprost | 42 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 39 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | 11 |
| Jardiance | Empagliflozin | 38 | 12 |
| Ammonium Lactate | Ammonium Lactate | 37 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 37 | 15 |
| Digoxin | Digoxin | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Klayesta | Nystatin | 35 | 17 |
| Levofloxacin | Levofloxacin | 34 | 25 |
| Mupirocin | Mupirocin | 34 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 22 |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 22 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Prednisone | Prednisone | 28 | 17 |
| Santyl | Collagenase Clostridium Hist. | 28 | 15 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | 14 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 24 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 19 |
| Xifaxan | Rifaximin | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | 11 |
| Lidocaine | Lidocaine | 22 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | 11 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Admelog Solostar | Insulin Lispro | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Nystop | Nystatin | 18 | 11 |
| Bethanechol Chloride | Bethanechol Chloride | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Tacrolimus | Tacrolimus | 17 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 13 |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ritonavir | Ritonavir | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | suppressed |
| Darunavir | Darunavir | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $295.41 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, TEZSPIRE, ZORYVE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error